Assuntos
Síndrome Hipereosinofílica/tratamento farmacológico , Transtornos Mieloproliferativos/tratamento farmacológico , Proteínas de Fusão Oncogênica/genética , Pirazóis/uso terapêutico , Adulto , Idoso , Feminino , Humanos , Síndrome Hipereosinofílica/genética , Leucemia , Masculino , Transtornos Mieloproliferativos/genética , Nitrilas , Pirimidinas , Indução de Remissão , Resultado do TratamentoRESUMO
Somatic mutations in the calreticulin (CALR) gene were recently discovered in patients with sporadic essential thrombocythemia (ET) and primary myelofibrosis (PMF) lacking JAK2 and MPL mutations. We studied CALR mutation status in familial cases of myeloproliferative neoplasm. In a cohort of 127 patients, CALR indels were identified in 6 of 55 (11%) subjects with ET and in 6 of 20 (30%) with PMF, whereas 52 cases of polycythemia vera had nonmutated CALR. All CALR mutations were somatic, found in granulocytes but not in T lymphocytes. Patients with CALR-mutated ET showed a higher platelet count (P = .017) and a lower cumulative incidence of thrombosis (P = .036) and of disease progression (P = .047) compared with those with JAK2 (V617F). In conclusion, a significant proportion of familial ET and PMF nonmutated for JAK2 carry a somatic mutation of CALR.
Assuntos
Calreticulina/genética , Mutação , Mielofibrose Primária/genética , Trombocitemia Essencial/genética , Análise Mutacional de DNA , Éxons/genética , Predisposição Genética para Doença , Genótipo , Humanos , Janus Quinase 2/genética , Estimativa de Kaplan-Meier , Linhagem , Fenótipo , Mielofibrose Primária/mortalidade , Trombocitemia Essencial/mortalidadeRESUMO
Patients with essential thrombocythemia may carry JAK2 (V617F), an MPL substitution, or a calreticulin gene (CALR) mutation. We studied biologic and clinical features of essential thrombocythemia according to JAK2 or CALR mutation status and in relation to those of polycythemia vera. The mutant allele burden was lower in JAK2-mutated than in CALR-mutated essential thrombocythemia. Patients with JAK2 (V617F) were older, had a higher hemoglobin level and white blood cell count, and lower platelet count and serum erythropoietin than those with CALR mutation. Hematologic parameters of patients with JAK2-mutated essential thrombocythemia or polycythemia vera were related to the mutant allele burden. While no polycythemic transformation was observed in CALR-mutated patients, the cumulative risk was 29% at 15 years in those with JAK2-mutated essential thrombocythemia. There was no significant difference in myelofibrotic transformation between the 2 subtypes of essential thrombocythemia. Patients with JAK2-mutated essential thrombocythemia and those with polycythemia vera had a similar risk of thrombosis, which was twice that of patients with the CALR mutation. These observations are consistent with the notion that JAK2-mutated essential thrombocythemia and polycythemia vera represent different phenotypes of a single myeloproliferative neoplasm, whereas CALR-mutated essential thrombocythemia is a distinct disease entity.
Assuntos
Calreticulina/genética , Janus Quinase 2/genética , Mutação , Trombocitemia Essencial/diagnóstico , Trombocitemia Essencial/genética , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Alelos , Transformação Celular Neoplásica/genética , Códon , Éxons , Feminino , Granulócitos , Humanos , Masculino , Pessoa de Meia-Idade , Transtornos Mieloproliferativos/genética , Policitemia Vera/genética , Mielofibrose Primária/genética , Prognóstico , Receptores de Trombopoetina/genética , Trombocitemia Essencial/mortalidade , Trombose/genética , Adulto JovemRESUMO
BACKGROUND: Approximately 50 to 60% of patients with essential thrombocythemia or primary myelofibrosis carry a mutation in the Janus kinase 2 gene (JAK2), and an additional 5 to 10% have activating mutations in the thrombopoietin receptor gene (MPL). So far, no specific molecular marker has been identified in the remaining 30 to 45% of patients. METHODS: We performed whole-exome sequencing to identify somatically acquired mutations in six patients who had primary myelofibrosis without mutations in JAK2 or MPL. Resequencing of CALR, encoding calreticulin, was then performed in cohorts of patients with myeloid neoplasms. RESULTS: Somatic insertions or deletions in exon 9 of CALR were detected in all patients who underwent whole-exome sequencing. Resequencing in 1107 samples from patients with myeloproliferative neoplasms showed that CALR mutations were absent in polycythemia vera. In essential thrombocythemia and primary myelofibrosis, CALR mutations and JAK2 and MPL mutations were mutually exclusive. Among patients with essential thrombocythemia or primary myelofibrosis with nonmutated JAK2 or MPL, CALR mutations were detected in 67% of those with essential thrombocythemia and 88% of those with primary myelofibrosis. A total of 36 types of insertions or deletions were identified that all cause a frameshift to the same alternative reading frame and generate a novel C-terminal peptide in the mutant calreticulin. Overexpression of the most frequent CALR deletion caused cytokine-independent growth in vitro owing to the activation of signal transducer and activator of transcription 5 (STAT5) by means of an unknown mechanism. Patients with mutated CALR had a lower risk of thrombosis and longer overall survival than patients with mutated JAK2. CONCLUSIONS: Most patients with essential thrombocythemia or primary myelofibrosis that was not associated with a JAK2 or MPL alteration carried a somatic mutation in CALR. The clinical course in these patients was more indolent than that in patients with the JAK2 V617F mutation. (Funded by the MPN Research Foundation and Associazione Italiana per la Ricerca sul Cancro.).
Assuntos
Calreticulina/genética , Mutação , Mielofibrose Primária/genética , Trombocitemia Essencial/genética , Doenças da Medula Óssea/genética , Éxons , Humanos , Janus Quinase 2/genética , Leucemia Mieloide/genética , Reação em Cadeia da Polimerase , Mielofibrose Primária/mortalidade , Modelos de Riscos Proporcionais , Receptores de Trombopoetina/genética , Análise de Sequência de DNA , Trombocitemia Essencial/complicações , Trombocitemia Essencial/mortalidade , Trombose/etiologiaRESUMO
Exome sequencing of primary tumors identifies complex somatic mutation patterns. Assignment of relevance of individual somatic mutations is difficult and poses the next challenge for interpretation of next generation sequencing data. Here we present an approach how exome sequencing in combination with SNP microarray data may identify targets of chromosomal aberrations in myeloid malignancies. The rationale of this approach is that hotspots of chromosomal aberrations might also harbor point mutations in the target genes of deletions, gains or uniparental disomies (UPDs). Chromosome 11 is a frequent target of lesions in myeloid malignancies. Therefore, we studied chromosome 11 in a total of 813 samples from 773 individual patients with different myeloid malignancies by SNP microarrays and complemented the data with exome sequencing in selected cases exhibiting chromosome 11 defects. We found gains, losses and UPDs of chromosome 11 in 52 of the 813 samples (6.4%). Chromosome 11q UPDs frequently associated with mutations of CBL. In one patient the 11qUPD amplified somatic mutations in both CBL and the DNA repair gene DDB1. A duplication within MLL exon 3 was detected in another patient with 11qUPD. We identified several common deleted regions (CDR) on chromosome 11. One of the CDRs associated with de novo acute myeloid leukemia (P=0.013). One patient with a deletion at the LMO2 locus harbored an additional point mutation on the other allele indicating that LMO2 might be a tumor suppressor frequently targeted by 11p deletions. Our chromosome-centered analysis indicates that chromosome 11 contains a number of tumor suppressor genes and that the role of this chromosome in myeloid malignancies is more complex than previously recognized.
Assuntos
Proteínas Adaptadoras de Transdução de Sinal/genética , Aberrações Cromossômicas , Cromossomos Humanos Par 11/genética , Proteínas de Ligação a DNA/genética , Proteínas com Domínio LIM/genética , Proteínas Proto-Oncogênicas/genética , Exoma/genética , Histona-Lisina N-Metiltransferase , Humanos , Leucemia Mieloide Aguda/genética , Síndromes Mielodisplásicas/genética , Proteína de Leucina Linfoide-Mieloide/genética , Policitemia Vera/genética , Reação em Cadeia da Polimerase , Mielofibrose Primária/genética , Proteínas Proto-Oncogênicas c-cbl/genética , Trombocitose/genéticaAssuntos
Transformação Celular Neoplásica/efeitos dos fármacos , Síndrome Hipereosinofílica/tratamento farmacológico , Proteínas de Fusão Oncogênica/genética , Pirazóis/administração & dosagem , Adulto , Transformação Celular Neoplásica/patologia , Doença Crônica , Feminino , Rearranjo Gênico , Humanos , Síndrome Hipereosinofílica/genética , Janus Quinases/antagonistas & inibidores , Nitrilas , Proteínas de Fusão Oncogênica/metabolismo , Pirimidinas , Indução de Remissão , Translocação GenéticaRESUMO
The classical BCR-ABL negative myeloproliferative neoplasms (MPN) polycythemia vera, essential thrombocythemia, and primary myelofibrosis are clonal hematopoietic disorders characterized by excessive production of terminally differentiated myeloid cells. In MPN patients, the disease can progress to secondary myelofibrosis or acute myeloid leukemia. Clonal hematopoiesis, disease phenotype, and progression are caused by somatically acquired genetic lesions of genes involved in cytokine signaling, RNA splicing, as well as epigenetic regulation. This review provides an overview of point mutations and cytogenetic lesions associated with MPN and addresses the role of these somatic lesions in MPN disease progression.
Assuntos
Epigênese Genética , Transtornos Mieloproliferativos/genética , Proteínas Adaptadoras de Transdução de Sinal , Aberrações Cromossômicas , DNA (Citosina-5-)-Metiltransferases/genética , DNA Metiltransferase 3A , Proteínas de Ligação a DNA/genética , Dioxigenases , Progressão da Doença , Humanos , Peptídeos e Proteínas de Sinalização Intracelular , Isocitrato Desidrogenase/genética , Janus Quinase 2/genética , Mutação , Complexo Repressor Polycomb 2/genética , Proteínas/genética , Proteínas Proto-Oncogênicas/genética , Proteínas Proto-Oncogênicas c-cbl/genética , Splicing de RNA , Receptores de Trombopoetina/genética , Proteínas Repressoras/genéticaRESUMO
The study aimed to identify genetic lesions associated with secondary acute myeloid leukemia (sAML) in comparison with AML arising de novo (dnAML) and assess their impact on patients' overall survival (OS). High-resolution genotyping and loss of heterozygosity mapping was performed on DNA samples from 86 sAML and 117 dnAML patients, using Affymetrix Genome-Wide Human SNP 6.0 arrays. Genes TP53, RUNX1, CBL, IDH1/2, NRAS, NPM1, and FLT3 were analyzed for mutations in all patients. We identified 36 recurrent cytogenetic aberrations (more than five events). Mutations in TP53, 9pUPD, and del7q (targeting CUX1 locus) were significantly associated with sAML, while NPM1 and FLT3 mutations associated with dnAML. Patients with sAML carrying TP53 mutations demonstrated lower 1-year OS rate than those with wild-type TP53 (14.3% ± 9.4% vs. 35.4% ± 7.2%; P = 0.002), while complex karyotype, del7q (CUX1) and del7p (IKZF1) showed no significant effect on OS. Multivariate analysis confirmed that mutant TP53 was the only independent adverse prognostic factor for OS in sAML (hazard ratio 2.67; 95% CI: 1.33-5.37; P = 0.006). Patients with dnAML and complex karyotype carried sAML-associated defects (TP53 defects in 54.5%, deletions targeting FOXP1 and ETV6 loci in 45.4% of the cases). We identified several co-occurring lesions associated with either sAML or dnAML diagnosis. Our data suggest that distinct genetic lesions drive leukemogenesis in sAML. High karyotype complexity of sAML patients does not influence OS. Somatic mutations in TP53 are the only independent adverse prognostic factor in sAML. Patients with dnAML and complex karyotype show genetic features associated with sAML and myeloproliferative neoplasms.
Assuntos
Aberrações Cromossômicas , Leucemia Mieloide Aguda/genética , Segunda Neoplasia Primária/genética , Aberrações Cromossômicas/estatística & dados numéricos , DNA/genética , Perfilação da Expressão Gênica , Estudo de Associação Genômica Ampla , Humanos , Estimativa de Kaplan-Meier , Cariotipagem , Leucemia Mieloide Aguda/mortalidade , Perda de Heterozigosidade , Análise Multivariada , Segunda Neoplasia Primária/mortalidade , Nucleofosmina , Análise de Sequência com Séries de Oligonucleotídeos , Polimorfismo de Nucleotídeo Único , PrognósticoRESUMO
Chronic myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS) have an inherent tendency to progress to acute myeloid leukemia (AML). Using high-resolution SNP microarrays, we studied a total of 517 MPN and MDS patients in different disease stages, including 77 AML cases with previous history of MPN (N = 46) or MDS (N = 31). Frequent chromosomal deletions of variable sizes were detected, allowing the mapping of putative tumor suppressor genes involved in the leukemic transformation process. We detected frequent deletions on the short arm of chromosome 6 (del6p). The common deleted region on 6p mapped to a 1.1-Mb region and contained only the JARID2 gene--member of the polycomb repressive complex 2 (PRC2). When we compared the frequency of del6p between chronic and leukemic phase, we observed a strong association of del6p with leukemic transformation (P = 0.0033). Subsequently, analysis of deletion profiles of other PRC2 members revealed frequent losses of genes such as EZH2, AEBP2, and SUZ12; however, the deletions targeting these genes were large. We also identified two patients with homozygous losses of JARID2 and AEBP2. We observed frequent codeletion of AEBP2 and ETV6, and similarly, SUZ12 and NF1. Using next generation exome sequencing of 40 patients, we identified only one somatic mutation in the PRC2 complex member SUZ12. As the frequency of point mutations in PRC2 members was found to be low, deletions were the main type of lesions targeting PRC2 complex members. Our study suggests an essential role of the PRC2 complex in the leukemic transformation of chronic myeloid disorders.
Assuntos
Transformação Celular Neoplásica/genética , Deleção Cromossômica , Cromossomos Humanos Par 6/ultraestrutura , Genes Supressores de Tumor , Síndromes Mielodisplásicas/genética , Transtornos Mieloproliferativos/genética , Proteínas de Neoplasias/fisiologia , Proteínas do Tecido Nervoso/fisiologia , Proteínas Supressoras de Tumor/fisiologia , Doença Aguda , Idoso , Proteínas de Transporte/genética , Aberrações Cromossômicas , Mapeamento Cromossômico , Cromossomos Humanos Par 6/genética , Proteínas de Ligação a DNA/deficiência , Proteínas de Ligação a DNA/genética , Progressão da Doença , Proteína Potenciadora do Homólogo 2 de Zeste , Feminino , Genótipo , Humanos , Leucemia Mieloide/genética , Masculino , Proteínas de Neoplasias/deficiência , Proteínas de Neoplasias/genética , Proteínas do Tecido Nervoso/deficiência , Proteínas do Tecido Nervoso/genética , Proteínas Nucleares/deficiência , Proteínas Nucleares/genética , Análise de Sequência com Séries de Oligonucleotídeos , Complexo Repressor Polycomb 2 , Proteínas do Grupo Polycomb , Proteínas Repressoras/deficiência , Proteínas Repressoras/genética , Proteínas Repressoras/fisiologia , Análise de Sequência de DNA , Fatores de Transcrição/deficiência , Fatores de Transcrição/genética , Proteínas Supressoras de Tumor/deficiência , Proteínas Supressoras de Tumor/genéticaRESUMO
The behavior of the enzymatic antioxidant defense system was studied in buckwheat leaves and seedlings subjected to short-term enhanced UV-B radiation. The effects of UV-B action were monitored immediately after irradiation as well as after recovery. The applied dose induced an increase in lipid peroxidation and total flavonoid content, a decrease in chlorophyll content, and a change in enzymatic digestibility of extracted DNA. The activity of superoxide dismutase (SOD), catalase (CAT), ascorbate peroxidase, and soluble peroxidase, as well as the isoelectric focusing (IEF) pattern of peroxidase isoforms, was analyzed. In treated as well as recovered seedlings, soluble and ascorbate peroxidase activities were increased. The activity of SOD was not altered, whereas CAT activity was decreased. In contrast to seedlings, only CAT activity was increased in treated and recovered leaves.